Macrophage inhibitory cytokine-1 (MIC-1/GDF15), CCAAT/enhancer binding protein delta (CEBPD) and neuroinflammtion

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1048921

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

I will develop new therapies for multiple sclerosis and spinal cord injury. I will also evaluate diagnostic and therapeutic uses for macrophage inhibitory cytokine-1 (MIC-1/GDF15) that was discovered in Australia. I will confirm its use in screening for bowel cancer. Also, I will look at using it in the indigenous and wider Australian community to improve health and close the gap in life expectancy. Finally, I will conduct trials of MIC-1/GDF15 therapy of obesity and inflammation.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2017

Funding Scheme: Career Development Fellowships

Funding Amount: $459,270.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Autoimmunity

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Aboriginal health | autoimmunity | colon cancer | macrophage inhibitory cytokine 1 (MIC-1) | multiple sclerosis (MS) | neuroinflammation | obesity | population health | population screening | spinal cord injury

Related Links